Battelle Pulmonary Therapeutics Changes Name to BattellePharma; Name Change Reflects Company's Position as a Specialty Pharmaceutical Company.Business Editors & Health/Medical Writers BIOWIRE2K COLUMBUS, Ohio--(BW HealthWire)--April 11, 2002 Battelle Pulmonary Therapeutics announced today that it has changed its name to BattellePharma to emphasize the company's position as a specialty pharmaceutical company. BattellePharma has a growing portfolio of nine products in development, with several in early clinical trials, to treat a variety of respiratory and systemic diseases and lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . "Since the company was founded in April 2000, we have made great strides toward accomplishing our mission of becoming a specialty pharmaceutical company with a broad pipeline of innovative proprietary and partnered products and inhalation technology platforms sought after by some of the most respected pharmaceutical companies in the world," said Dennis B. Cearlock, president, director and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BattellePharma. "The new name BattellePharma communicates our organization's mission to leverage cutting-edge science and engineering to design more effective medicines." BattellePharma's products are based on three proprietary platforms: Mystic(TM) inhalation technology, novel formulation technologies, and inhaled anticancer therapy. The company has partnerships with numerous pharmaceutical corporations, including Abbott Laboratories, GlaxoSmithKline, Pfizer, Inc., Viasys Healthcare, and ViroPharma, Inc., and is a subsidiary of Battelle Memorial Institute The Battelle Memorial Institute is a private not-for-profit applied science and technology development company headquartered in Columbus, Ohio. The institute opened in 1929 but traces its origins to the 1923 will of Ohio industrialist Gordon Battelle which provided for its , the world's largest independent and private research and development organization. BattellePharma achieved several milestones this past year, including the company's cancer therapy, Resmycin(TM) (doxorubicin doxorubicin /doxo·ru·bi·cin/ (dok?so-roo´bi-sin) an antineoplastic antibiotic, produced by Streptomyces peucetius, which binds to DNA and inhibits nucleic acid synthesis; used as the hydrochloride salt and as a liposome-encased HCI (Human Computer Interaction) Refers to the design and implementation of computer systems that people interact with. It includes desktop systems as well as embedded systems in all kinds of devices. inhalation solution) receiving fast track status from the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and several key manufacturing agreements with ALP (language) ALP - A list processing extension of Mercury Autocode. ["ALP, An Autocode List-Processing Language", D.C. Cooper et al, Computer J 5:28-31, 1962]. , a division of Cardinal Industries, Bespak, and HiTek Power. The company's strong intellectual property position includes 48 patents, patent applications and patents in preparation, not counting foreign equivalents. BattellePharma employs 55 experienced scientific, engineering and management professionals at its headquarters in Columbus, Ohio. BattellePharma is launching an updated version of its website to coincide with the name change. Learn more about BattellePharma at www.battellepharma.com. Note to Media: The BattellePharma logo is available via LogoLink(TM) on Business Wire's Home Page at www.businesswire.com. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion